You dont have to be obese to try a GLP-1. Lose the last ten pounds. Get your summer body faster. Many videos feature women who are already thin explaining they only want to lose a few pounds
The study results also showed that dysesthesia and urinary tract infections were reported in around one in ten patients on the highest doses of retatrutide but they were generally mild-to-moderate symptoms and the majority were resolved during treatment, while most participants continued taking retatrutide
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NASH) Nature Medicine (2024) A substudy of the Phase 2 obesity trial, published in Nature Medicine, examined retatrutide's effects in participants with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD)
Cardiovascular outcomes trials in type 2 diabetes: where do we go from here
Ready to explore whether GLP-1 therapy is right for you
When evaluating retatrutide research data, the safety profile appears manageable and consistent with the GLP-1/GIP/glucagon receptor agonist class
